EUVIMEDEUVIMED entdecken
Crossref

Addressing False Positives in High-Sensitivity Troponin I Testing: Mitigation Strategies

Ruhan Wei, Bruce Lobaugh, Donna Kirsch, Jieli Li iD, Michael Datto

The Journal of Applied Laboratory Medicine · 04.11.2024 · 9 (6) · 1104-1106

DOI: 10.1093/jalm/jfae086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 06.08.2024. Verfasst von Ruhan Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Duke University Medical Center, Durham, NC 27710, United States. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While cardiac troponin I (cTnI) is the preferred cardiovascular biomarker, fibrin and microclots can cause falsely elevated results and are common in samples from urgent or emergent patient encounters because the sample conditions from such draws are often suboptimal. Carryover from samples with very high cTnI levels to contaminate otherwise negative samples can be another cause of falsely elevated cTnI measurements. After testing a sample with a >270 000 ng/L hsTnI result, Beckman Coulter, the manufacturer of the Access high-sensitivity troponin I (hsTnI) assay, recommends discarding all open hsTnI reagent packs from the instrument. Only after loading a fresh reagent pack, running the low hsTnI QC on all reagent pipettors, and repeating each positive hsTnI sample that was elevated, is it appropriate to initiate another run of samples (1). However, this approach does not account for possible cross-contamination across the system to other non-hsTnI reagent packs. It also does not consider the fact that such samples may not be immediately identified until dilution is completed, which could lead to the premature release of spurious false positive results. Herein, we describe the mitigation strategies to reduce the hsTnI false positive rate and minimize the impact of carryover. At our institution, most hsTnI samples are collected as a temporal series at baseline, 1, and 3 hours after the initial patient presentation. Prior to this study, samples were collected in BD (Becton–Dickinson and Company) Vacutainer® Lithium Heparin Plasma Separator Tubes. Results are interpreted using different algorithms depending on the patient encounter location and the length of symptoms. Both the absolute and the delta values between the 1-hour and baseline and the 3-hour and baseline collections are used for interpretation at patient triage. HsTnI concentrations may either trend up, trend down, or remain the same during this time. However, after the initial implementation of this assay, we observed patients with physiologically untenable patterns: not detected or low baseline and 3-hour hsTnI measurements with extremely high 1-hour measurements (up to hundreds of ng/L). After consultation with the manufacturer, we found that these sporadic, falsely elevated results could always be corrected after re-centrifuging and retesting an aliquot from the initial sample. To further investigate, the following steps were conducted to quantify the number of falsely elevated results. Whenever a pattern occurred that was biologically impossible or improbable, the sample was aliquoted, re-centrifuged, and retested. Samples with a decrease after retesting that changed the interpretation or merited result correction were designated as “falsely elevated.” The percentage of total samples that were falsely elevated between May 18, 2022 and July 17, 2022 was 0.71% (48/6798). Although the review and recentrifugation protocol is effective, it is highly labor-intensive and inefficient. Further, identifying the falsely elevated results in real time is challenging, and the entire process increases turnaround time. To address this, the laboratory evaluated the BD Vacutainer Rapid Serum Tube (RST). Previous studies have demonstrated that RST reduces the false positive rate in conventional cardiac troponin T and I and high-sensitivity troponin T assays (2–4). The use of RST significantly reduced the rate of falsely elevated hsTnI measurements to 0.19% (57/30 000), as evaluated between October 8, 2022 and June 5, 2023. To address carryover, the following strategies are employed after discussion with the manufacturer. First, only one of the 4 reagent pipettors is dedicated for hsTnI analysis to eliminate cross-contamination between hsTnI and non-hsTnI reagent packs. Second, a middleware rule is used to prevent the affected analyzer from autovalidating any hsTnI results following a result that exceeds the upper limit of quantification. This rule also halts subsequent samples for hsTnI measurement from autoloading on that effected analyzer from the automation line until the issue is resolved. Furthermore, a high hsTnI result triggers an auto-onboard dilution rule. If the final hsTnI result falls within the analytical reportable range, it is autoverified, and testing can resume. However, if the result is outside the analytical reportable range, the following actions are taken: (a) repeat any subsequent hsTnI specimens with detectable concentrations analyzed and autoverified prior to halting hsTnI testing; and (b) if >5 tests remain in the reagent pack, analyze sample diluent to check for any potential carryover issues. Finally, a daily carryover check using the sample diluent is performed to ensure the reagent pack is not contaminated before testing patient samples. These measures offer an efficient and effective safeguard against intraassay carryover problems while minimizing unnecessary reagent waste. Fibrin, microclots, and carryover can cause false positive hsTnI results. Laboratories need to work with manufacturers to develop internal processes that can mitigate those common interferences. Possible solutions include collecting samples with RST, dedicating a specific reagent pipettor, implementing middleware rules, and performing daily carryover checks. Vendors should continue to develop mitigation strategies and modify instrumentation to improve system performance, and improve assay specificity and optimizing instrument configuration. This study was approved by the Duke University Health System Institutional Review Board. Protocol ID: Pro00115768. Author Contributions: The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Ruhan Wei (Conceptualization-Equal, Data curation-Equal, Formal analysis-Equal, Investigation-Equal, Writing—original draft-Equal), Bruce Lobaugh (Conceptualization-Equal, Investigation-Equal, Writing—review & editing-Equal), Donna Kirsch (Data curation-Equal, Investigation-Equal, Writing—review & editing-Equal), Jieli Li (Writing—review & editing-Equal), and Michael Datto (Conceptualization-Equal, Supervision-Equal, Writing—review & editing-Equal) Authors’ Disclosures or Potential Conflicts of Interest: No authors declared any potential conflicts of interest.

Autor:innen und Institutionen

  • Department of Pathology, Duke University Medical Center, Durham, NC 27710, United States.
  • Duke University Health System Clinical Laboratories, Duke Health, Durham, NC 27710, United States.
  • Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, United States.

ORCID-Profile: Jieli Li

Zitieren

APA

Wei, R., Lobaugh, B., Kirsch, D., Li, J., & Datto, M. (2024). Addressing False Positives in High-Sensitivity Troponin I Testing: Mitigation Strategies. The Journal of Applied Laboratory Medicine, 9(6), 1104-1106. https://doi.org/10.1093/jalm/jfae086

Vancouver

Wei R, Lobaugh B, Kirsch D, Li J, Datto M. Addressing False Positives in High-Sensitivity Troponin I Testing: Mitigation Strategies. The Journal of Applied Laboratory Medicine. 2024;9(6):1104-1106. doi:10.1093/jalm/jfae086

BibTeX
@article{Wei2024,
  author = {Wei, Ruhan and Lobaugh, Bruce and Kirsch, Donna and Li, Jieli and Datto, Michael},
  title = {Addressing False Positives in High-Sensitivity Troponin I Testing: Mitigation Strategies},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2024},
  volume = {9},
  number = {6},
  pages = {1104--1106},
  doi = {10.1093/jalm/jfae086}
}
Kostenlos starten →